Page last updated: 2024-12-05

2-phenylbutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Phenylbutyric acid (2-PBA) is a chiral molecule with a wide range of applications in medicine and organic chemistry. It is known to inhibit histone deacetylase (HDAC) activity, which can have implications for various biological processes, including inflammation, cancer, and neurodegenerative disorders. The compound can be synthesized through various methods, including the Friedel-Crafts acylation of benzene with butyryl chloride followed by hydrolysis. 2-PBA is studied extensively for its potential therapeutic uses, including treatment of inflammatory disorders and certain types of cancer. It is also explored as a potential neuroprotective agent in Alzheimer's disease and Parkinson's disease. The ability of 2-PBA to modulate HDAC activity makes it a promising lead compound for drug development in these areas.'

2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7012
CHEMBL ID1616045
CHEBI ID86545
SCHEMBL ID1715
MeSH IDM0118729

Synonyms (110)

Synonym
2-phenylbutanoate
nsc1860
benzeneacetic acid, .alpha.-ethyl-
.alpha.-phenyl butyric acid
butyric acid, 2-phenyl-
2-phenylbutyric acid
2-phenylbutanoic acid
.alpha.-phenylbutyric acid
.alpha.-toluic acid, .alpha.-ethyl-
wln: qvy2&r
nsc-1860
90-27-7
DIVK1C_006993
ai3-11228
nsc 1860
einecs 201-982-5
brn 0509876
alpha-phenyl butyric acid
alpha-phenylbutyric acid
alpha-toluic acid, alpha-ethyl-
SPECTRUM_001673
SPECTRUM5_001396
BSPBIO_003447
alpha-ethylphenylacetic acid
benzeneacetic acid, alpha-ethyl-
2-phenylbutyric acid, 98%
KBIO3_002667
KBIO1_001937
KBIOGR_001212
KBIO2_004721
KBIO2_002153
KBIOSS_002153
KBIO2_007289
SPECPLUS_000897
SPECTRUM2_000510
SPBIO_000439
SPECTRUM3_001664
SPECTRUM4_000626
inchi=1/c10h12o2/c1-2-9(10(11)12)8-6-4-3-5-7-8/h3-7,9h,2h2,1h3,(h,11,12
AC-10409
BMSE000617
(+/-)-2-phenylbutyric acid
P0164
2-ethyl-2-phenylacetic acid
AKOS000120324
A843486
2-phenyl-butyric acid
STL163589
BBL012274
s7s079h2c2 ,
2-09-00-00356 (beilstein handbook reference)
unii-s7s079h2c2
FT-0605052
FT-0613342
FT-0605258
S6086
AKOS016040111
SCHEMBL1715
a-ethylphenylacetic acid
(+)2-phenylbutyric acid
phenyl butanoic acid
2-phenylburyric acid
cambridge id 5132265
W-100334
chebi:86545 ,
CHEMBL1616045
BS-3887
(.+/-.)-2-phenylbutanoic acid
(.+/-.)-2-phenylbutyric acid
.alpha.-phenyl-n-butyric acid
.alpha.-ethylphenylacetic acid
alpha-ethyl-alpha-toluic acid
primidone impurity e [ep impurity]
(+/-)-2-phenylbutanoic acid
(rs)-2-phenylbutanoic acid
mfcd00002667
J-520787
F2191-0104
(+/-)-2-phenylbutyric acid, vetec(tm) reagent grade, 98%
(2rs)-2-phenylbutanoic acid; primidone imp. e (ep); primidone impurity e
(2rs)-2-phenylbutanoic acid
2-phenylbutanoicacid
2-phenylbutyrate
alpha-ethylbenzeneacetic acid
a-ethyl-a-toluic acid
alpha-phenylbutyrate
alpha-ethylphenylacetate
a-phenylbutyric acid
a-phenylbutyrate
a-ethylphenylacetate
a-ethyl-a-toluate
a-ethylbenzeneacetate
alpha-ethyl-alpha-toluate
alpha-ethylbenzeneacetate
(rs)-2-phenylbutanoate
a-ethylbenzeneacetic acid
DTXSID90861682
HY-W017194
Q27159231
(4-carboxyphenyl)acetone
?-ethylphenylacetic acid; (+/-)-2-phenylbutyric acid; (rs)-2-phenylbutanoic acid; 2-ethyl-2-phenylacetic acid
primidone impurity e
EN300-20606
AMY40956
E78161
CS-W017910
SB44765
SY036812
PD065554
Z104479150
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1149920Inhibition of fatty acid biosynthesis from [1-14C]acetate in rat liver slices at 1 X 10'-3 M relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149917Inhibition of cholesterol biosynthesis from [1-14C]acetate in rat liver slices at 1 X 10'-3 M relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (28.57)18.7374
1990's2 (9.52)18.2507
2000's4 (19.05)29.6817
2010's8 (38.10)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.96 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index42.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]